RNA-seq, WES and miRNA-array for GCT cell lines and their cisplatin-resistant variants
The aim of this study was to identify prognostic molecular signatures for GTC patients derived from comprehensive molecular characterization of cisplatin-resistant variants of established GCT cell lines. GCT cell lines and their isogenic cisplatin-resistant variants (2102Ep, NCCIT, NT2, JAR, JEG3, NOY1, NCR-G1, and TCam2) were profiled by RNA-, microRNA-, and whole-exome sequencing (WES).
The aim of this study was to identify prognostic molecular signatures for GTC patients derived from comprehensive molecular characterization of cisplatin-resistant variants of established GCT cell lines. GCT cell lines and their isogenic cisplatin-resistant variants (2102Ep, NCCIT, NT2, JAR, JEG3, NOY1, NCR-G1, and TCam2) were profiled by RNA-, microRNA-, and whole-exome sequencing (WES).